HTHyon-Xhi Tan

Hyon-Xhi Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Hyon-Xhi Tan has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolution of immunity to SARS-CoV-2

    by Adam K. Wheatley, Jennifer A. Juno, Jing J. Wang, Kevin J. Selva, Arnold Reynaldi, Hyon-Xhi Tan, Wen Shi Lee, Kathleen M. Wragg, Hannah G. Kelly, Robyn Esterbauer, et al.

    The durability of infection-induced SARS-CoV-2 immunity has major implications for public health mitigation and vaccine development. Animal studies 1,2 and the scarcity of confirmed re-infection 3 suggests immune protection is likely, although the durability of this protection is debated. Lasting immunity following acute viral infection requires maintenance of both serum antibody and antigen-specific memory B and T lymphocytes and is notoriously pathogen specific, ranging from life-long for smallpox or measles 4 , to highly transient for common cold coronaviruses (CCC) 5 . Neutralising antibody responses are a likely correlate of protective immunity and exclusively recognise the viral spike (S) protein, predominantly targeting the receptor binding domain (RBD) within the S1 sub-domain 6 . Multiple reports describe waning of S-specific antibodies in the first 2-3 months following infection 7-12 . However, extrapolation of early linear trends in decay might be overly pessimistic, with several groups reporting that serum neutralisation is stable over time in a proportion of convalescent subjects 8,12-17 . While SARS-CoV-2 specific B and T cell responses are readily induced by infection 6,13,18-24 , the longitudinal dynamics of these key memory populations remains poorly resolved. Here we comprehensively profiled antibody, B and T cell dynamics over time in a cohort recovered from mild-moderate COVID-19. We find that binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection, as expected, with a similar decline in S-specific CD4+ and circulating T follicular helper (cTFH) frequencies. In contrast, S-specific IgG+ memory B cells (MBC) consistently accumulate over time, eventually comprising a significant fraction of circulating MBC. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent subjects to 74 days, with probable additive protection from B and T cells. Overall, our study suggests SARS-CoV-2 immunity after infection is likely to be transiently protective at a population level. SARS-CoV-2 vaccines may require greater immunogenicity and durability than natural infection to drive long-term protection.


  • Open Access

    Prime-boost protein subunit vaccines against SARS-CoV-2 are highly immunogenic in mice and macaques

    by Hyon-Xhi Tan, Jennifer A Juno, Wen Shi Lee, Isaac Barber-Axthelm, Hannah G Kelly, Kathleen M Wragg, Robyn Esterbauer, Thakshila Amarasena, Francesca L Mordant, Kanta Subbarao, et al.

    Summary: SARS-CoV-2 vaccines are advancing into human clinical trials, with emphasis on eliciting high titres of neutralising antibodies against the viral spike (S). However, the merits of broadly targeting S versus focusing antibody onto the smaller receptor binding domain (RBD) are unclear. Here we assessed prototypic S and RBD subunit vaccines in homologous or heterologous prime-boost regimens in mice and non-human primates. We find S is highly immunogenic in mice, while the comparatively poor immunogenicity of RBD was associated with limiting germinal centre and T follicular helper cell activity. Boosting S-primed mice with either S or RBD significantly augmented neutralising titres, with RBD-focussing driving moderate improvement in serum neutralisation. In contrast, both S and RBD vaccines were comparably immunogenic in macaques, eliciting serological neutralising activity that generally exceed levels in convalescent humans. These studies confirm recombinant S proteins as promising vaccine candidates and highlight multiple pathways to achieving potent serological neutralisation.


  • Open Access

    Coformulation with tattoo ink for immunological assessment of vaccine immunogenicity in the draining lymph node

    by Isaac M Barber-Axthelm, Hannah G Kelly, Robyn Esterbauer, Kathleen Wragg, Anne Gibbon, Wen Shi Lee, Adam K Wheatley, Stephen J Kent, Hyon-Xhi Tan, Jennifer A Juno

    Characterisation of germinal centre B and T cell responses yields critical insights into vaccine immunogenicity. Non-human primates are a key pre-clinical animal model for human vaccine development, allowing both lymph node and circulating immune responses to be longitudinally sampled for correlates of vaccine efficacy. However, patterns of vaccine antigen drainage via the lymphatics after intramuscular immunisation can be stochastic, driving uneven deposition between lymphoid sites, and between individual lymph nodes within larger clusters. In order to improve the accurate isolation of antigen-exposed lymph nodes during biopsies and necropsies, we developed and validated a method for co-formulating candidate vaccines with tattoo ink, which allows for direct visual identification of vaccine-draining lymph nodes and evaluation of relevant antigen-specific B and T cell responses by flow cytometry. This approach improves the assessment of vaccine-induced immunity in highly relevant non-human primate models.


  • Open Access

    Suboptimal SARS-CoV-2-specific CD8 + T-cell response associated with the prominent HLA-A*02:01 phenotype

    by Jennifer R Habel, Thi H O Nguyen, Carolien E van de Sandt, Jennifer A Juno, Priyanka Chaurasia, Kathleen Wragg, Marios Koutsakos, Luca Hensen, Xiaoxiao Jia, Brendon Chua, et al.

    An improved understanding of human T-cell-mediated immunity in COVID-19 is important if we are to optimize therapeutic and vaccine strategies. Experience with influenza shows that infection primes CD8 + T-cell memory to shared peptides presented by common HLA types like HLA-A2. Following re-infection, cross-reactive CD8 + T-cells enhance recovery and diminish clinical severity. Stimulating peripheral blood mononuclear cells from COVID-19 convalescent patients with overlapping peptides from SARS-CoV-2 Spike, Nucleocapsid and Membrane proteins led to the clonal expansion of SARS-CoV-2-specific CD8 + and CD4 + T-cells in vitro , with CD4 + sets being typically robust. For CD8 + T-cells taken directly ex vivo , we identified two HLA-A*02:01-restricted SARS-CoV-2 epitopes, A2/S 269–277 and A2/Orf1ab 3183–3191 . Using peptide-HLA tetramer enrichment, direct ex vivo assessment of the A2/S 269 + CD8 + and A2/Orf1ab 3183 + CD8 + populations indicated that the more prominent A2/S 269 + CD8 + set was detected at comparable frequency (∼1.3×10 −5 ) in acute and convalescent HLA-A*02:01 + patients. But, while the numbers were higher than those found in uninfected HLA-A*02:01 + donors (∼ 2.5×10 −6 ), they were low when compared with frequencies for influenza-specific (A2/M1 58 ) and EBV-specific (A2/BMLF 1280 ) (∼ 1.38×10 −4 ) populations. Phenotypic analysis ex vivo of A2/S 269 + CD8 + T-cells from COVID-19 convalescents showed that A2/S 269 + CD8 + T-cells were predominantly negative for the CD38, HLA-DR, PD-1 and CD71 activation markers, although the majority of total CD8 + T-cells were granzyme and/or perforin-positive. Furthermore, the bias towards naïve, stem cell memory and central memory A2/S 269 + CD8 + T-cells rather than effector memory populations suggests that SARS-CoV2 infection may be compromising CD8 + T-cell activation. Priming with an appropriate vaccine may thus have great value for optimizing protective CD8 + T-cell immunity in COVID-19.


  • Open Access

    Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19

    by Jennifer A Juno, Hyon-Xhi Tan, Wen Shi Lee, Arnold Reynaldi, Hannah G Kelly, Kathleen Wragg, Robyn Esterbauer, Helen E Kent, C Jane Batten, Francesca L Mordant, et al.

    The rapid global spread of SARS-CoV-2 and resultant mortality and social disruption have highlighted the need to better understand coronavirus immunity to expedite vaccine development efforts. Multiple candidate vaccines, designed to elicit protective neutralising antibodies targeting the viral spike glycoprotein, are rapidly advancing to clinical trial. However, the immunogenic properties of the spike protein in humans are unresolved. To address this, we undertook an in-depth characterisation of humoral and cellular immunity against SARS-CoV-2 spike in humans following mild to moderate SARS-CoV-2 infection. We find serological antibody responses against spike are routinely elicited by infection and correlate with plasma neutralising activity and capacity to block ACE2/RBD interaction. Expanded populations of spike-specific memory B cells and circulating T follicular helper cells (cTFH) were detected within convalescent donors, while responses to the receptor binding domain (RBD) constitute a minor fraction. Using regression analysis, we find high plasma neutralisation activity was associated with increased spike-specific antibody, but notably also with the relative distribution of spike-specific cTFH subsets. Thus both qualitative and quantitative features of B and T cell immunity to spike constitute informative biomarkers of the protective potential of novel SARS-CoV-2 vaccines.


  • Open Access

    Distinct systems serology features in children, elderly and COVID patients

    by Kevin J. Selva, Carolien E. van de Sandt, Melissa M. Lemke, Christina Y. Lee, Suzanne K. Shoffner, Brendon Y. Chua, Thi H.O. Nguyen, Louise C. Rowntree, Luca Hensen, Marios Koutsakos, et al.

    SARS-CoV-2, the pandemic coronavirus that causes COVID-19, has infected millions worldwide, causing unparalleled social and economic disruptions. COVID-19 results in higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive coronavirus immunological responses, induced by circulating human coronaviruses, is critical to understand such divergent clinical outcomes. The cross-reactivity of coronavirus antibody responses of healthy children (n=89), adults (n=98), elderly (n=57), and COVID-19 patients (n=19) were analysed by systems serology. While moderate levels of cross-reactive SARS-CoV-2 IgG, IgM, and IgA were detected in healthy individuals, we identified serological signatures associated with SARS-CoV-2 antigen-specific Fcγ receptor binding, which accurately distinguished COVID-19 patients from healthy individuals and suggested that SARS-CoV-2 induces qualitative changes to antibody Fc upon infection, enhancing Fcγ receptor engagement. Vastly different serological signatures were observed between healthy children and elderly, with markedly higher cross-reactive SARS-CoV-2 IgA and IgG observed in elderly, whereas children displayed elevated SARS-CoV-2 IgM, including receptor binding domain-specific IgM with higher avidity. These results suggest that less-experienced humoral immunity associated with higher IgM, as observed in children, may have the potential to induce more potent antibodies upon SARS-CoV-2 infection. These key insights will inform COVID-19 vaccination strategies, improved serological diagnostics and therapeutics.